Our Pipeline | Theravance Biopharma

Clinical Programs

We apply insights and innovation at each stage of our business and utilize our internal capabilities and those of our partners around the world. The table below summarizes the status of our key programs for internal development or co-development.

YUPELRI^®

Phase 1

Phase 2

Phase 3

Filed

Marketed

Phase 4

YUPELRI^®- US
(revefenacin)
LAMA

VIATRIS

COPD Patients with
Suboptimal PIFR

Phase 4

YUPELRI^®- China
(revefenacin)
LAMA

VIATRIS

COPD Patients

Phase 3

Pipeline Asset

Phase 1

Phase 2

Phase 3

Filed

Marketed

Phase 4

Ampreloxetine
Norepinephrine
reuptake
inhibitor

FULLY OWNED

Symptomatic
Neurogenic
orthostatic
hypotension
(nOH)

Phase 3

Outlicensed Program

Phase 1

Phase 2

Phase 3

Filed

Marketed

Phase 4

Skin-Selective JAKi

Pfizer

Topical skin-selective pan-JAKi

Phase 1

Economic Interest

TRELEGY
FF/UMEC/VI

COPD and Asthma

Marketed

Glossary

COPD
Chronic Obstructive Pulmonary Disease

FF
Fluticasone Furoate

JAK inhibitor
Janus kinase inhibitor

nOH
Neurogenic Orthostatic Hypotension

UMEC
Umeclidinium

VI
Vilanterol

PHASE 1
Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug

PHASE 2
Further clinical safety testing and preliminary efficacy testing in a limited patient population

PHASE 3
Evaluation of clinical efficacy and safety within an expanded patient population

FILED
A marketing application has been submitted to a regulatory authority